Abstract
To Editor,
We were deeply intrigued by the article by Schricker et al 1 titled “Effects of a Mind-Body Medicine Group Program for Cancer Patients: A Retrospective Cohort Study.” Through a retrospective cohort design, the authors focused on an 11-week structured Mind-Body Medicine (MBM) group program, validating its efficacy in improving multidimensional symptoms such as quality of life, fatigue, and anxiety in cancer patients within a real-world clinical setting. Particularly innovative was the identification of “baseline sleep quality” as a core predictor of intervention effectiveness, filling a gap in real-world research on the differential efficacy of MBM across various tumor types and stages.
We highly commend the study’s contribution to the field of integrative oncology. However, in order to enhance the clinical translational value of its findings, we believe it is crucial to discuss some potential limitations not addressed in the article. Below is a detailed analysis.
Firstly, the study assessed only the immediate outcomes at the conclusion of the MBM intervention. Current cutting-edge research commonly adopts long-term longitudinal follow-up designs (≥12 months) to evaluate the sustainability of intervention effects. 2 The lack of such a design prevents the verification of the MBM program’s “maintenance effect” on cancer patients’ fatigue, sleep disturbances, and other symptoms. Moreover, this omission precludes a direct comparison with studies that suggest “MBM reduces symptom recurrence rates,” thereby limiting the study’s relevance in informing long-term clinical treatment strategies.
Secondly, although the study comprehensively assessed outcomes such as quality of life and fatigue using standardized questionnaires like FACT-G, MFI, and HADS, it did not incorporate any objective biomarkers reflecting the function of the “neuroendocrine-immune (NEI) axis.” This omission means that the study does not fully align with the current trend in MBM research toward “integrated assessments of subjective symptoms and physiological indicators.” 3 As a result, the intervention’s underlying biological mechanisms remain insufficiently supported.
Furthermore, while the study mentions that the MBM program includes modules like mindfulness meditation, yoga, and body awareness exercises, it does not provide detailed implementation specifics or standardized operating procedures (SOPs). The absence of tools such as an “intervention integrity checklist” to clearly define operationalized intervention protocols and control dosage complicates the replication of the intervention by other research teams. 4 This also hinders the exploration of the relationship between intervention dosage and effect intensity, limiting the program’s feasibility and scalability across diverse healthcare settings.
In conclusion, Schricker et al’s study, through a real-world retrospective cohort design, demonstrated the potential of an 11-week structured MBM group program in improving multidimensional symptoms in cancer patients. Future studies could further advance MBM from “real-world preliminary validation” to “precision-based clinical implementation” by: extending follow-up periods to assess the sustainability of effects; incorporating objective biomarkers reflecting the neuroendocrine-immune axis to explore mechanisms; developing standardized intervention protocols; and clarifying the relationship between intervention dosage and efficacy. Such improvements would lay a strong scientific foundation for developing personalized MBM intervention protocols based on patient baseline characteristics. Ultimately, these optimizations could pave the way for more targeted strategies to enhance the long-term quality of life of cancer patients and refine the supportive care system in oncology.
